Despite their potential, these therapies—HA, PRP, IRAP, ACS, APS, and the secretome—still require further clinical validation to develop standardized protocols, optimize dosing regimens, and confirm their long-term safety and efficacy. This evidence concerns the gene IL1RN and autoimmune polyendocrinopathy.